'/%3E%3C/svg%3E){kind=small}
Unlock the full value of your oncology innovation !
MATWIN offers an accelerating program aiming at challenging and maximizing innovation transfer potential exclusively on oncology. Through a support course, candidates will have access to support through expertise, coaching/mentoring and a qualified network of partners likely to help them accelerate the development of their project.
The program is open to International candidates (academic team or start-up) developing an innovative R&D product or solution in oncology, such as therapeutics, diagnostics, medical devices, medtechs, technological platforms and AI tools. Consult different support paths’ details below.
You can also access MATWIN’s expertise on an ad hoc basis at any time through tailor-made services. (see “Tailor-made service offers” section)
MATWIN's presentation of the accelerating program
Want to learn more about the programme and hear directly from former participants?
Join us on October 20, 2026 – 12:30 PM for a dedicated webinar featuring two MATWIN alumni:
Matthias Stein Gerlach – Kydo Therapeutics
Patrick Korman – Unguard Therapeutics
They will share their experience of the MATWIN programme and discuss how the support helped them develop and strengthen their projects.
Matwin program
Restricted to academic teams or young startups needing to optimize their project's strenght and having only preclinical results available before the regulatory tox for therapeutic innovations or ante validation / CE marking for diagnostic tests/medical devices
1/ Submit application
2/ Preselection pitch
3/ Jury’s decision
4/ 2 personalized coaching sessions + 1h Board mentoring
5/ MATWIN International Board interview
To apply
Eligibility requirements
- Innovative R&D project (service offers (e.g. CRO services) will be automatically discarded)
- Original and innovative target, MoA, marker/biomarker, technological approach
- Strength of intellectual property (patent application filed or pending)
- Maturity: if product: established preclinical in vivo (or early clinical) POC, MoA, SAR, associated biomarker if diagnostic test: selectivity, specificity, impact on the therapeutic choice...
Program advantages
- Become familiar with market expectations by accessing the expertise of an international network of peers, pharmas / biotechs / investors
- Optimize the industrial structuring of the project and enhance its development potential
- Obtain development plan validation guidelines (clinical positioning, indications, milestones, etc.)
- Become investor-ready while reducing their go-to-market risk
- Increase the project’s, visibility and accelerate its promotion for the benefit of patients